← All trials
NCT04407000
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Jun 22, 2020
- Completion date
- Jul 20, 2020
- First posted
- May 29, 2020
- Last posted
- May 29, 2020
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.Lead sponsor
- Farmagen Ar-Ge Biyot. Ltd. StiOverall official - principal investigator
- Farmagen Ar-Ge Biyot. Ltd. StiCollaborator
- Novagenix Bioanalytical Drug R&D CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.